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ABSTRACT
Background: HIV in pregnancy is one of the commonly documented challenge and pregnancy
complication and HIV positive pregnant women are at a significantly increased risk of adverse
pregnancy outcomes such as lower birth weight, preterm birth and perinatal death. Identifying
factors associated with the adverse birth outcome would lead to better improvement in
intervention.
Objective: the objective of this study was to assess the prevalence and associated factors of
low birth weight and preterm birth among infant born to HIV infected women in Public Hospitals
in North Gondar, Northwest Ethiopia.
Methods: Institutional based cross-sectional study was conducted. All infant born to HIV
infected women during September 1, 2009 to April 30, 2012 was included in the study by
extracting recorded data of the mothers and infant birth in public hospitals of North Gondar
Zone, Northwest Ethiopia. Then both bivariate and multivariate-logistic regression was
performed using 95% confidence interval and respective odds ratio was determined.
Result: Out of 416 singletons infant born to HIV infected mothers the prevalence of low birth
weight and preterm delivery was 89(21.4 %) and 69(16.6 %) respectively. Baseline maternal
CD4 count level below 200cells/mm3 [AOR (95%C.I.)= 4.24(1.85, 9.69)], maternal BMI below
18.5 [AOR (95%C.I.)= 5.50(2.82, 10.74)], gestational age at birth below 37weeks, [AOR
(95%C.I) =28.14(12.69, 62.34)] and maternal exposure to HAART [AOR (95%C.I) =8.26(2.53,
14.24)] were factors significantly associated with LBW. On the other hand, baseline maternal
CD4 level below 200/mm3[AOR(95%CI)= 5.37(1.89, 15.49)],having no PMTCT intervention
during pregnancy [AOR (95%C.I) =1.53(1.24, 3.05)], maternal BMI less than
18.5[AOR(95%C.I)=4.50(2.39, 9.27)], mother who had already started HAART before
pregnancy [AOR(95%C.I)=1.82(1.02,3.81)] were factors associated with preterm delivery.
Conclusion and recommendation: This study showed that the prevalence of low birth weight
and preterm delivery among infant born to HIV positive mothers is very high. Maternal low
baseline CD4 level, low BMI, exposure to HAART, and preterm delivery were associated factors
of LBW, and similarly, low baseline maternal CD4 level, low BMI,having no PMTCT intervention
and maternal being on HAART before pregnancy were factors associated with PD.
The programme for PMTCT services should give attention in early identification of those
mothers with predicted complication like those with low CD4 level or advanced clinical stage, to
link them to appropriate intervention like family planning, and timely treatment intervention and
infection-prevention.
11. INTRODUCTION
1.1 Statement of the problem
Human immunodeficiency virus continues to take a heavy toll on women and children
worldwide(1). In 2008, 33.4 million individuals were living with HIV, of whom 15.7 million
were women and 2.1 million were children under 15 years of age (1, 2) and about 3
million people are currently estimated to be receiving antiretroviral therapy(ART) in low-
and middle income countries of which 56% of people receiving ART were women.(1)
HIV infection in pregnancy has become the most common complication of pregnancy in
some developing countries. WHO thus now recommends the initiation of HAART in
pregnancy for all HIV-infected women with CD4 cell counts <350 cells/mm3 irrespective
of WHO clinical staging, and for all women in WHO clinical stage 3 or 4, irrespective of
the CD4 cell count and as a PMTCT option for all HIV-infected women (3) to maximize
prevention of HIV transmission and maternal and infant survival(3, 4) .
Based on this in 2009, 53% of the estimated HIV-infected pregnant women worldwide
received at least some antiretroviral (ARV) drugs to prevent HIV transmission to their
child (5).
In Ethiopia In 2009, there were an estimated 84,189 HIV-positive pregnancies and
14,093 HIV-positive births and based on the single point estimate of HIV/AIDS
prevalence of HAPCO and has estimated HIV prevalence of 2.4% with more than 1
million people living with HIV in 2010 (6, 7)
Early HAART initiation for all HIV-positive pregnant women (2, 8) and widespread use of
HAART among HIV infected pregnant women has led to dramatic decreases in HIV
transmission to the infant (9, 10) and decreases maternal morbidity(11-13). Currently,
MTCT prevention programs in sub-Saharan African countries include zidovudine and
Lamivudine during the final weeks of pregnancy and sd-NVP at delivery.(2, 4, 14)
However, HIV infection, use of such medications during pregnancy for which adverse
pregnancy and fetal outcomes are not completely known and many uncertainities
remain regarding potential adverse effects of HAART initiation and use in pregnancy on
the birth outcome. Low birth weight and preterm delivery are the commonly reported
adverse outcomes among HIV infected women (13).
2An adverse Birth outcome like low birth weight and preterm birth is associated with
maternal HIV infection, maternal CD4 level, duration on HAART, time of HAART
initiation and type of HAART regimen. The risk of having a low-birth-weight baby was
substantially and significantly increased with maternal HIV infection. But still there
remain controversies in between different studies in different countries (15-17).
Based on epidemiological observations that infants weighing less than 2,500 g are
approximately 20 times more likely to die than heavier babies (18).More than 20 million
infants worldwide, representing 15.5 per cent of all births are born with low birth weight,
95.6 per cent of them in developing countries. Low birth weight levels in sub-Saharan
Africa are around 15 per cent.
Existing research on the determinants of LBW also focuses primarily on nutritional
determinants in industrialized countries. LBW is caused by retarded growth in utero,
shortened gestation, or both. Low prepregnancy weight and poor pregnancy weight gain
have been identified as the strongest determinants of intrauterine growth retardation
leading to LBW(19) .
This study was aimed at identifying the prevalence and associated factors of low birth
weight and preterm delivery among infant born to HIV infected mothers. The study was
conducted in the Public Hospitals in North Gondar, Northwest Ethiopia.
31.2 Literature Review
Birth outcome can be affected by maternal prepregnancy related infections and
nutritional status and on pregnancy weight gain other related factors including on
pregnancy drug intake, infections and complications. Low birth weight is defined as
newborn birth weight below 2.5kg at birth and preterm birth is defined as birth of infant
at below 37 complete weeks of gestation according to WHO(20). Current studies are
revealing the high occurrence of low birth weight and preterm birth among HIV infected
pregnant women.
Preterm birth and low birth weight are the most common direct cause of newborn
mortality. Preterm birth and SGA, which are the reasons for low-birth-weight (LBW), are
also important indirect causes of neonatal deaths. LBW contributes to 60% to 80% of all
neonatal deaths. The global prevalence of LBW is 15.5%, which amounts to about 20
million LBW infants born each year, 96.5% of them in developing countries. Countries
can reduce their neonatal and infant mortality rates by improving the care of LBW
infants mortality(21).
1.2.1 Maternal HIV infection and Birth Outcome
Human immunovirus (HIV) is the leading cause of morbidity and mortality among
women of reproductive age. It has been estimated that, 1.4 million HIV-infected women
gave birth in low- and middle-income countries in 2008 where 91% of whom reside in
sub-Saharan Africa.(2)
In Ethiopia the prevalence of HIV among those pregnant mothers who underwent HIV
testing is 8% where the number of HIV positive pregnant mothers identified per year has
increased from 4,172 in 2006 to 13,257 in 2010 and 53% of known HIV-positive
mothers and 48% of known HIV-exposed infants have received ARV prophylaxis
according to recent five-year national level PMTCT data analysis(7).
While HIV/AIDS is not a major direct cause of neonatal death, maternal HIV status
affects newborn survival by causing an increased risk of preterm,lowbirth weight and
death in the neonatal period and infancy, even among those babies who do not become
HIV-positive.(22) Newborns of HIV-positive women are more likely to be very low birth
4weight (LBW), preterm and have low Apgar scores, placing them at greater risk of
death. The interaction of HIV with other infections and the indirect effects of HIV, such
as poverty and maternal illness, also contribute to poor outcomes for newborns. (23)
Early studies on the association between maternal HIV infection and adverse perinatal
outcome showed as there appears to be an association, between maternal HIV
infection and an adverse perinatal outcome(24). A cohort studies have reported that
prematurity was almost twice more frequent in infant born to HIV positive women than
infant born to HIV negative women. The proportion of LBW infants was twice as high as
among newborn of HIV positive women than HIV negative women. Similarly, the
frequency of IUGR was almost three times higher in infant born to HIV positive women
than HIV negative women(25, 26).HIV infection is associated with PTD, with a 2.5-fold
increased risk. HIV infection conferred a 2.1-fold increased risk for spontaneous PTD,
and a 3.2-fold increased risk for iatrogenic PTD.(27) .Recent longitudinal study
conducted in china indicated the prevalence of LBW and Preterm delivery among 194
HIV-positive mothers which was 19.6% and 9.8% , respectively(28).
A longitudinal study conducted in 2007 in South Africa found that an adverse pregnancy
outcome was independently associated with HIV-infected women and Birth weight was
inversely associated with maternal HIV(16).
Studies from Kenya showed HIV-infected women were 3 times more likely to deliver a
low birth- weight baby, especially in the presence of HIV-related symptoms (25, 29) and
in Rwanda also , low birth weight was significant in babies of asymptomatic women than
in babies born to uninfected women(23).Findings of  study in Mozambique showed as
there was a trend towards increased rates among HIV-positive women for most of these
outcomes  and  infants born to HIV-positive women had more than twice a higher risk of
death than infants born to HIV-negative women(14).
As to the study in India, compared with infants of HIV-infected women enrolled during
antenatal, infants of HIV-infected women enrolled in the post-partum ward had a higher
risk of pre-term delivery (20% versus 8%) and LBW (41% versus 22%) and the
prevalence of low birth weight infants among HIV-infected pregnant women was
12.6%(30).
51.2.2 Maternal ARV exposure and birth outcome
During pregnancy, healthcare providers in high income countries recommend initiation
of HAART for all HIV-infected women in order to reduce viral load, improve maternal
health, and prevent perinatal HIV transmission(31). In some resource-poor settings,
initiating HAART has been recommended only for pregnant women with more advanced
HIV disease [i.e., CD4 cell count<200 cells/ml (<250 cells/ml) or HIV-related symptoms
and CD4 cell count<350 cells/ml] (32).
Antenatal provision of cotrimoxazole for HIV-infected pregnant women with low CD4 cell
counts may have indirect benefits for neonatal health(33). Antenatal provision of
cotrimoxazole for HIV-infected pregnant women with low CD4 cell counts have reduced
trends in low birth weight, preterm delivery and  neonatal mortality as compared to
those HIV infected mother not on antenatal cotrimoxazole prophylaxis and similarly co-
trimoxazole reduces chorioamnionitis with associated reduction in severe pre-term
delivery rates and improved infant mortality as to study conducted in USA(34) and
zambia (35).
Mother to child transmission rates were lower in women who became pregnant on
HAART than those initiating HAART during pregnancy and Late initiation of HAART is
associated with increased risk of MTCT(36).However, HAART exposure was associated
with an increased preterm birth rate and more advanced immune-suppression was a
risk factor for low birth weight and preterm birth (15, 37-39). Indeed, in HIV-infected
women taking HAART, iatrogenic PTD contributes up to 40% of the overall prematurity.
The use of HAART during the second half of pregnancy was strongly associated with
iatrogenic PTD compared with women untreated during pregnancy (27).
Various types of ARVs drug and no ARV were associated with LBW. Low birth weight
infants delivered from HIV-infected pregnant women with and without ART were 9.9%
(7/41) and 13.6% (19/159), respectively. The one who received HAART had 2.27 times
higher risk in having LBW (40) and women who were using ARVs pre-conception had
higher rates of LBW  and PTD (33.3% vs 16.5% and (26.3% vs. 17.7%) respectively
(38, 41). In line with this study conducted by European collaborative study observed a
2.1-fold increased risk when HAART was started  before pre-conception and 1.9-fold
6increased risk of delivery at  less than 37 weeks of gestation when HAART was started
late during pregnancy (42, 43)and the risk of delivery before 34 weeks’ gestation was
increased by 2.5-fold for those starting combination ARV regimens during pregnancy
and 4.4-fold for those entering pregnancy on combination ARV regimens(42).
This study is also supported by study conducted in Poland (39) which revealed that
Pre-term deliveries were highly prevalent among women on HAART during pregnancy,
especially when therapy was started before or in the first trimester of pregnancy and
women receiving HAART with PI were at a higher risk of delivering a baby with low birth
weight.
Compared with 2-drug therapy, women who did not take ARV drugs, as well as those
who took only 1-drug or 3-drug combinations had increased risks of preterm birth as
indicated on study in USA (44) and low birth weight was associated with a history of
illicit maternal drug use, unknown maternal HIV status before delivery, symptomatic
maternal HIV disease, and infant HIV infection and preterm birth was associated with a
history of illicit maternal drug use, symptomatic maternal HIV disease, no ART, receipt
of a 3-drug HAART regimen with PIs, and infant HIV infection. But exposure to
monotherapy was not associated with prematurity as European collaborative study (41)
In contrast, the use of multiple ARV drugs compared with no drugs or treatment with
one drug was not associated with increased rates of preterm labor, low birth weight, low
Apgar scores, or stillbirth (45) nor were any significant associations between adverse
pregnancy outcome and use of ARV drugs by class/regimen or by category (including
combination ARV regimens) found in an analysis from the Women and Infants
Transmission Study (WITS) and study in England(46, 47). Additionally prospective
cohort study of 681 women from South American and Caribbean countries who
received at least 1 antiretroviral drug did not find a significant association between
premature delivery and ART during pregnancy (48) and meta-analysis of 14 European
and American clinical studies found no increase in risk of PD with either any ARV drug
receipt compared with no drugs or combination of ARV regimens including PIs
compared with no drugs (12) and  the risk of LBW and stillbirth were not increased in
any drug regimen groups(49).
7Several studies from sub-Saharan Africa also suggested that HIV-infected mothers may
be at increased risk of adverse pregnancy outcomes (50) and enhanced  prenatal care
is important to improved birth outcomes among HIV-Infected women (51) and recent
cohort study in Nigeria has shown that compared to HIV infected mother who where on
HAART during early pregnancy Intrauterine growth restriction (IUGR), PD, frequency of
LBW were significantly higher among women with untreated-HIV infection in
pregnancy(52).
A study in Abidjan, Côte d’Ivoire, compared women eligible for HAART from two
cohorts, each with approximately 150 women(53) . LBW was two-fold higher in the
cohort that took three-drug HAART compared with the cohort that received two-drug,
short-course ARV prophylaxis for preventing MTCT. LBW rates were highest in those
who had initiated HAART prior to pregnancy. A larger study in Botswana found that
HAART-exposed infants were smaller for gestational age than unexposed infants (54).
Specific HAART regimens, early exposure to any regimen was associated with PD
compared with HAART-unexposed infants. Women receiving HAART with PI were at a
higher risk of delivering a baby with low birth weight.(39) It should be noted that women
who received PI-containing HAART had more advanced HIV disease or had
experienced failure of other antiretroviral regimens; advanced maternal HIV disease is a
recognized risk factor for preterm delivery (9, 55, 56) Among women with early HAART-
exposure, higher rates of LBW were observed in women receiving Efavirenz based
regimens compared with nevirapine and PIs-based regimens. Even though there were
no differences in rates of LBW by regimen in the late HAART initiated group(15).
A prospective study in Germany and Austria also indicated that use of antenatal PI-
based HAART initiated before or during pregnancy was associated with a significantly
increased risk of premature delivery [AOR =3.40], compared with monotherapy. the
mean birth weight z-score for children exposed to HAART with PI or dual therapy  was
slightly but significantly higher than that for those exposed to monotherapy(57).However
other study showed that combination of ARV with PI was not significantly associated
with spontaneous preterm birth, compared to ARV without PI and Low birth weight
result is similar. (58)
81.2.3 Maternal immunity level and birth outcome
As CD4 level is also the main correlates of adverse pregnancy outcome as the study
reveals, women with a CD4 count <200 cells/mL were nearly twice as likely to have an
adverse pregnancy outcome than those with a cell count of 500 cells/mL or more (16)
and With each 50 cells/mm3 increase in CD4 cell count associated with a 57%
reduction in the odds of LBW (15-17, 59).
These studies are also supported by study in china indicating Lower CD4 cell count;
<100 cell/μl and CD4 cell count 100–199 cells/μl compared to CD4 ≥350 cells/μl and
higher HIV RNA viral load [≥100 000 copies/ml at enrollment, gestational age at delivery
(<37 weeks) were associated with higher risk for LBW. But for PD, only maternal
injection drug use as the route of HIV transmission compared to those infected with HIV
through sexual transmission was significantly associated with a higher risk of preterm
delivery. Mothers infected through drug use were 5.30-fold more than those infected via
sexual transmission.(28)
However, one recent multi-centric study depicted as there is no difference in LBW and
PD among cohort of mothers with <200 CD4 cells and  >500 CD4 cells respectively(60)
Finally study dealing with the birth outcome particularly of low birth weight and preterm
birth among HIV infected women is limited in Ethiopia and the current study thus will be
an opportunity for information and better improvement of newborn health care.
91.3 Justification of the study
Though the government of Ethiopia is working towards achievement of the reduction of
prevention of HIV transmission from mother to child as to the recommendation of WHO
and country level guideline, some evaluative study for the outcome of the treatment and
PMTCT is also very valuable for programe evaluation and intervention. Different studies
in different countries remarked and find out different infant birth outcome and factors
associated with; among HIV infected women and most of the studies are in
controversies.
Particularly in Ethiopia there was no study assessing the infant birth outcome
particularly on low birth weight and preterm birth among HIV infected mothers as far as
the best of my knowledge is concerned.
Thus the present study was aimed to identify the associated factors of low birth weight
and preterm birth among infant born to HIV infected women in Public Hospitals and the
study will be the helpful in improvement in medical care for infants, for programmers,
community workers and policy makers and also to improve the health outcome of
infants in child health programme.
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2. OBJECTIVES
2.1 General Objectives
To assess the prevalence and associated factors of Low birth weight and preterm birth
among infant born to HIV infected mothers in Public Hospitals in North Gondar,
Northwest Ethiopia
2.2 Specific Objectives
 To determine the prevalence of low birth weight among infant born to HIV infected
women in Public Hospitals
 To determine the prevalence of preterm birth among infant born to HIV infected
women in Public Hospitals
 To identify factors associated with low birth weight among infant born to HIV infected
women in Public Hospitals
 To identify factors associated with preterm birth among infant born to HIV infected
women in Public Hospitals
11
3. METHODS
3.1 Study design and period
Institutional based cross-sectional study design was conducted using data extraction
format to get data of infant-mother pairs retrospectively from hospital records among
infant born to HIV positive women in Public Hospitals during September 1, 2009 to April
10, 2012.
3.2 Study area and setting
The study was conducted in the three Public Hospitals of North Gondar, Northwest
Ethiopia (namely Gondar University Hospital, Metema Hospital and Debark Hospital)
from March to April 10, 2012. North Gondar Zone is located about 725 km North west of
Addis Ababa having a population of about 3,461,225 (61).In the Zone there are 3
government Hospitals, 29 health centers and 449 health posts. According to ANC
sentinel surveillance done in 2007, the prevalence of HIV Among antenatal attendants
is 3.9%.PMTCT service in the Zone initiated in 2005 and currently there are more than
23 PMTCT clinics in the Zone (62).
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Figure1.The study area (Gondar, Metemma and Debark Hospitals) in North Gondar, Ethiopia
3.3 Source and study population
All Infant born from HIV infected women during September 1, 2009, to April 30, 2012,
was the source and as well as the study population.
Ethiopia
North Gondar Zone
= Study areaLegend
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3.4 Sample size and sampling procedure
Taking 50 % prevalence study since no study in area, 5% margin of error, and 95%
confidence interval the sample size was calculated using single population proportion
formula to determine minimum sample size as follows:n = . p. (1 − p)n1 = ( . ) ( . )( . )( . )
n=384
Thus the final minimum sample size to be involved will be 384. As to sampling
procedure all infant born to HIV infected mothers from September 1, 2009 to April 10,
2012 was included in the study population.
3.5 Variables of Study
Dependent variable:
Birth weight and Gestational age at birth
Independent variables:
 Socio-demographic factors of mother :
Age, parity/gravidity, educational level, religion, occupation, marital status
 Current Obstetric factors:
Obstetric complications, Mode of labor and delivery
 Maternal nutritional status (maternal anemia,BMI,Wt gain during pregnancy)
 Maternal immunity status:
CD4 level, WHO clinical stage
 ARVs and related treatment factors:
Type of PMTC (prophylaxis/HAART) ,Time of HAART initiation,
Median duration on HAART, ARVs regimen/type
Cotrimoxazole prophylaxis, Treatment for other co-infections
Treatment for malaria
 Co-infections or OIs during pregnancy
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3.6 Inclusion and Exclusion criteria
Inclusion criteria:
All infant birth from HIV infected women at Public Hospitals during September 2009,
to April 2012
Exclusion criteria:
Twin birth
Incomplete or not available infant record
3.7 Operational definitions
Low birth weight (LBW): is defined as a birth weight below 2.5 kg and very low birth
weight (VLBW) as less than 1.5 kg.
Preterm delivery (PD): is defined as birth before 37 completed weeks of pregnancy
and extremely preterm birth was defined at birth before 34 weeks of pregnancy.
Untreated HIV positive pregnant women: are HIV infected pregnant mothers who had
not received antiretroviral drugs during the antenatal period but received nevirapine in
labour, also referred to as untreated-maternal HIV infection
3.8 Data collection procedure and quality assurance
The data from HMIS record of the delivery chart and PMTCT / ART follow up chart was
extracted which was obtained using pretested and checked data extraction form. The
mother PMTCT data was recorded on all information or characteristics including
Sociodemographic, maternal weight and enrollment BMI, current and previous obstetric
history, drug use and antiretroviral treatment history during ANC follow up, at the ART
follow up and during the delivery. The data in the health institution was completed by
medical doctors and/or nurses during the follow up of mothers. The information
extraction from records was done by using the chart number and identification of mother
from PMTCT/ART and delivery charts. BMI was determined by using the mother’s
prepregnancy weight and Height from their ART/pre-ART follow up.
Gestational age used is those determined by a clinician at the antenatal visit, using a
combination of ultrasound (when available), last menstrual period and symphyseal
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fundal height examination. The data was extracted by both trained data collection
assistant and investigator and the data quality or completeness was checked each time
the data obtained.
3.9 Data processing and statistical analysis
Data was entered into Epi info version 3.5.3 and transported to SPSS statistical soft
ware version 20 and data was coded, entered, cleaned and analyzed using SPSS.
Relevant variables were explained by frequency tables, graphs and Summary statistics.
Maternal information analyzed included demographic characteristics, obstetric history,
HIV diseases status, antiretroviral drug (ARV) history including CD4 cell count and
WHO stage of disease. The birth outcome evaluated were LBW (<2500 g) and PD
(gestational age <37 weeks). Maternal demographic, clinical and obstetrical
characteristics were examined within two groups divided by birth weight (<2500 g and
≥2500 g) or gestational age (<37 weeks and ≥37 weeks) for statistical significance by
Logistic regression analysis. For two variables (Maternal BMI and pregnancy weight
gain) which were having high missing values sensitivity test was done after performing
multiple imputation. Multivariate Logistic regression analysis was used to explore the
potential risk factors for LBW and PD. All variables in the Univariate analysis with P
value less than 0.2 were entered into multivariate models using backward stepwise
logistic regression. Variables were held in the models if they reached a significance
level of P value <0.05. Odds ratio and 95% confidence intervals were also constructed
along with its corresponding p-value.
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3.10 Ethical clearance
Ethical clearance was obtained from Ethical Review Board of Institute of Public Health
College of Medicine and Health Sciences, University of Gondar. Confidentiality of data
was kept by avoiding or restricting the use of data by others. Permission was obtained
from medical director of the hospital or institutions of data collections.
Confidentiality was ensured from all the data collectors and principal investigator side
via using code numbers and keeping questionnaires restricted. No individual patient
consent was deemed necessary as this was an anonymous chart/database review.
Personal information remained confidential and personal practices were not identified.
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5. RESULT
5.1 Sociodemographic factors
A total of 416 babies of HIV infected women who born in the hospitals were included in
the study. The mean age of the mothers was 27.27[ +4.5] and 361(86.8 %) are
Orthodox in religion. Majority, 360(86.5 %) were from urban and about half of the
mother were housewife. While about 181(45.7 %) were uneducated, 103(25.7 %) and
84(20.7 %) attended primary and secondary school respectively. About 262(63 %) are
in marriage, while 76(18.3%) of mothers have divorced. Table 1 shows the
Sociodemographic characteristics of the mothers
Table 1: Sociodemographic characteristics of the HIV positive mothers who gave
birth in Public Hospitals of North Gondar, Northwest Ethiopia from September
2009 to April 30, 2012
characteristics Frequency percent
Age of mother (years)
<19
20-25
26-30
>31
Total
7
146
189
74
416
1.7
35.1
45.4
17.8
100.0
Residence
Urban
rural
total
360
53
413
86.5
12.7
99.30
Religion
Orthodox
Muslim
Others
Total
361
43
5
409
86.8
10.3
1.2
98.30
Educational status
Uneducated
Primary school
Secondary school
College
Higher degree
Total
181
103
84
28
3
399
43.5
24.8
20.2
6.7
0.7
95.90
Occupation of the mother
Housewife
Daily laborer
Merchant
Local drinking seller
220
76
37
11
52.90
18.30
8.9
2.6
18
Gov’t employee
No occupation
Total
31
34
409
7.5
8.2
98.3
Marital status
Single
Married
Divorced
Widowed
Separated
Total
38
262
76
24
14
414
9.1
63
18.3
5.8
3.4
99.5
Pregnancy history
Primigravida
Multigravida
Total
123
280
403
29.6
67.3
96.9
5.2 Maternal HIV disease status and ARV treatment related factors
About 200(48.07 %) mothers were on HAART, and 130(31.25 %) were on pre-ART and
given PMTCT prophylaxis during pregnancy and the rest were initiated none and no
PMTCT intervention. Out of those mothers who were on HAART where 72(36 %) were
already started before their pregnancy and 128(64%) have started on pregnancy
respectively.
The mean CD4 count level of the mothers during pregnancy was 354.6[+156.8], and the
baseline pregnancy WHO clinical stage of the women were stage I, 106(25.5%), stage II
139(33.4%), stage III ,97(23.3%) and stage IV 71(17.1%). About 22(5.3 %), 44(10.6 %),
19(4.6 %) and 26(6.3%) of mothers had record of opportunistic infection related
diagnosis of TB, UTI and bacteruria, STI and chronic diarrhea during pregnancy
respectively.
5.3 current obstetric history related factors
About 346(83.2%), 45(10.8%), and 25(6%) delivery was spontaneous,
assisted/instrumental and operative delivery respectively. Only 8.6% of labor was
induced. About 20(4.8 %), 22(5.3%), 14(3.4 %) and 39(9.4 %) of mothers had history of
APH, Anemia, eclamsia and PROM during the pregnancy. The mean pregnancy weight
gain was 7.6 with +3.4SD and the mean BMI of mothers was 20.5 with+2.58SD.About
8(1.9%) and 4(1%) of mothers had history of HTN and DM during pregnancy.
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Out of 416 infant born to HIV infected mother 224(53.8%) were female and where
377(90.6%) were alive and there were 9(2.2%), 4(1.0%) and 24(5.8%) still birth,
congenital malformation and early neonatal death respectively.
Table 2:  HIV disease status, ARV use and obstetric factors of the HIV positive
mothers who gave birth in Public Hospitals of North Gondar, Northwest Ethiopia
from September 2009 to April 30, 2012
Factors frequency percent
WHO clinical stage
Stage I
Stage II
Stage III
Stage IV
total
106
139
97
71
413
25.5
33.4
23.3
17.1
99.3
CD4count level(cells/mm3)
<200
201-350
>350
total
84
122
181
387
20.2
29.3
43.5
93.02
ARV exposure
none
HAART
Prophylaxis
total
86
200
130
416
20.7
48.1
31.3
100.0
Time HAART started
Before pregnancy
On pregnancy
total
72
128
200
17.3
30.8
48.1
PMTCT intervention
no
yes
total
86
330
416
20.7
79.3
100.0
Infection
UTI and bacteruria
Tuberculosis
STI
Chronic diarrhea
none
total
44
22
19
26
279
390
10.6
5.3
4.6
6.3
67.06
93.75
Mode of labor
induced
spontaneous
total
36
380
416
8.7
91.3
100.0
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Mode of delivery
Spontaneous vaginal
Induced/assisted
Operative
total
346
45
25
416
83.2
10.8
6.0
100.0
Maternal BMI
<18.5
>=18.5
total
77
270
347
18.5
64.9
83.4
Obstetric complications
APH
Anemia
Eclamsia
PROM
none
total
20
22
14
39
311
406
4.8
5.3
3.4
9.4
74.8
97.7
Infant Birth outcome
alive
Still birth
Early neonatal death
Congenital malformation
total
374
13
25
4
416
89.9
3.1
6.0
1.0
100.0
Sex of the infant
male
female
total
192
224
416
46.2
53.8
100.0
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5.4 Prevalence of Low birth weight and preterm delivery
Out of 416 singleton infant born to HIV infected mothers the prevalence of low birth
weight was 89(21.4 %) with the mean birth weight of 2734.38[+457.33] and the
prevalence of preterm delivery was 69(16.6 %). About 55(79.7 %) of preterm were low
birth weight. Compared with infants of HIV infected mother who were not exposed to
HAART during pregnancy, infants of HIV infected mother who were exposed to HAART
had higher prevalence of LBW (5.6% Vs 38.5%) and similarly, compared with Infants of
HIV-infected women who were enrolled in PMTCT (either HAART or Prophylaxis),
infants of HIV-infected women who were not enrolled in PMTCT had higher prevalence
of pre-term delivery (11.6% Vs 23.9%).
The prevalence of LBW and preterm delivery is higher in those mothers with CD4 level
below 200cells/mm3 as compared to those having above 350cells/mm3 (46.4% Vs
11.0%) and (45.2% Vs 6.6%) respectively.
The prevalence of LBW among those mothers who were in WHO clinical stage
III,33(34.0%) and stage IV, 25(35.2%) were higher than among those in stage
I,14(13.2%) and stage II,17(12.2%)and similarly the prevalence of Preterm delivery was
23(32.4%),29(29.9%),10(7.2%) and 7(6.6%) in those in clinical stage IV,III,II and stage I
respectively.
Related to obstetric complication the prevalence of low birth and preterm delivery was
14(63.6%), 4(28.6%), 12(30.8%) and the prevalence of preterm delivery was 8(46.4%),
5(35.7%) and 13(33.3%) among those mother having anemia, Eclamsia and PROM
respectively.
The following table 3, shows the prevalence of LBW and PD with some selected factors
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Table 3: prevalence of LBW and PD among infant born to HIV positive mothers in
Public Hospitals of North Gondar, Northwest Ethiopia, from September 2009 to
April 2012
Factors Low birth Weight Preterm Delivery
Frequency percent frequency percent
Age of mother
<19
20-25
26-30
>31
1
35
36
17
14.3
24.0
19.0
17.0
1
28
28
12
14.3
19.2
19.2
16.2
Residence
Urban
Rural
76
12
21.1
22.6
58
10
16.1
18.9
Educational status
Uneducated
Primary school
Secondary school
Tertiary/College
Higher degree
40
27
11
8
0
22.1
26.2
13.1
28.6
0.0
33
21
9
3
0
18.2
20.4
10.7
10.7
0.0
Maternal occupation
Housewife
Daily laborer
Merchant
Local drinking seller
Gov’t employee
No occupation
46
24
5
1
7
5
20.9
31.6
13.5
9.1
22.6
14.7
40
19
3
0
3
3
18.2
25.0
8.1
0.0
9.7
8.8
Marital status
Single
Married
Divorced
Widowed
Separated
11
47
19
6
6
28.9
17.9
25.0
25.0
42.9
6
41
14
5
3
15.8
15.6
18.4
20.8
21.4
Pregnancy history
Primigravida
Multigravida
29
59
23.6
21.1
23
44
18.7
15.7
Obstetric complications
None
APH
Anemia
Eclamsia
PROM
56
2
14
4
12
18.0
10.0
63.6
28.6
30.8
40
2
8
5
13
12.9
10.0
36.4
35.7
33.3
BMI
<18.499
>18.5
43
40
55.8
14.8
34
27
44.2
10.0
23
Infections/OIs
STI
TB
UTI & bacteruria
Chronic diarrhea
9
9
10
7
47.4
40.9
22.7
26.9
10
11
10
4
45.5
50.0
24.4
15.4
PMTCT intervention
No
Yes
45
24
13.6
27.9
79
10
23.9
11.6
HAART exposure
No
Yes
12
77
5.6
38.5
25
44
11.6
22.0
Time HAART initiated
Before pregnancy
On pregnancy
44
33
61.1
25.8
22
22
30.6
17.2
ARV intervention
None
HAART
Prophylaxis
10
77
2
11.6
38.5
1.5
24
44
1
27.9
22.0
0.80
CD4 level (cell/mm3)
<200
201-350
>351
39
30
20
46.4
24.6
11.0
38
19
12
45.2
15.6
6.6
WHO clinical stage
I
II
III
IV
14
17
33
25
13.2
12.2
34.0
35.2
7
10
29
23
6.6
7.2
29.9
32.4
Gestational age at birth
>=37 weeks
<37weeks
34
55
9.8
79.7
Mode of labor
Induced
Spontaneous
5
84
13.9
22.1
6
63
16.7
16.6
Mode of delivery
Spontaneous vaginal
Assisted/instrumental
Operative
77
8
4
22.3
17.8
16.0
56
8
5
16.2
17.8
20.0
24
Figure 2. The prevalence of low birth weight with the types of PMTCT intervention given
for HIV positive women who gave birth in Public Hospitals in North Gondar Zone,
Northwest Ethiopia during September1, 2009 to April 30, 2012
5.5 Factors associated with low birth weight and preterm delivery
The multivariate analysis of factors associated with LBW showed that baseline maternal
CD4 count level below 200cells/mm3 [AOR (95%C.I.)= 4.24(1.85, 9.69)], maternal BMI
below 18.5 [AOR (95%C.I.)= 5.50(2.82, 10.74)], gestational age at birth below 37weeks,
[AOR (95%C.I)=28.14(12.69, 62.34)] and maternal exposure to HAART [AOR (95%C.I)
=8.26(2.53, 14.24)] were significantly associated with LBW. Those mother who were
having CD4 count level below 200cells/mm3 had 4.2 times higher risk of having low
birth weight as compared to those mothers with CD4 level above 350cells/mm3. As
compared those mothers who were not exposed to HAART mothers who were taking
HAART during pregnancy had 8.2 fold increased risk of having low birth Weight.
On the other hand, baseline maternal CD4 level below 200/mm3[AOR(95%CI)=
5.37(1.89, 15.49)],having no PMTCT intervention during pregnancy [AOR (95%C.I) =
1.53(1.24, 3.05)],maternal BMI less than 18.5[AOR(95%C.I)=4.50(2.39, 9.27)], mother
who started HAART before pregnancy [AOR(95%C.I)=1.82(1.02,3.81)] were associated with
preterm delivery.
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Mothers who had no PMTCT intervention had 1.63 times higher risk of having preterm
birth as compared to those mothers who had PMTCT intervention. Moreover, mother
who had started HAART before pregnancy had 1.82 fold increased risk of preterm
delivery as compared those mothers who started on the pregnancy.
Table 4: Univariate analysis of factors associated with birth weight and
gestational age at delivery among infant born to HIV positive mothers in Hospitals
of North Gondar, Northwest Ethiopia from September1, 2009 to April 10, 2012.
Factors LBW PD
yes no P value yes no P value
Age of mother
<19
20-25
26-30
>31
1
35
36
17
6
111
153
57
0.68
1
28
28
12
6
118
161
62
0.76
Residence
Urban
Rural
76
12
284
41
0.80
58
10
302
43
0.61
Educational status
Uneducated
Primary school
Secondary school
Tertiary/College
Higher degree
40
27
11
8
0
141
76
73
20
3
0.33
33
21
9
3
0
148
82
75
25
3
0.53
Maternal occupation
Housewife
Daily laborer
Merchant
Local drinking seller
Gov’t employee
No occupation
46
24
5
1
7
5
174
52
32
10
24
29
0.24
40
19
3
0
3
3
180
57
34
11
28
31
0.23
Marital status
Single
Married
Divorced
Widowed
Separated
11
47
19
6
6
27
215
57
18
8
0.19
6
41
14
5
3
32
221
62
19
11
0.97
Pregnancy history
Primigravida
Multigravida
29
59
94
221
0.43
23
44
100
236
0.75
26
Obstetric complications
None
APH
Anemia
Eclamsia
PROM
56
2
14
4
12
255
18
8
10
27
0.001
40
2
8
5
13
271
18
14
9
26
0.001
BMI
<18.499
>18.5
43
40
34
230
<0.0001
34
27
43
243
<0.0001
PMTCT intervention
No
Yes
10
79
76
251
0.015
24
45
62
285
0.002
HAART exposure
No
Yes
12
77
204
123
<0.0001
25
44
191
156
0.005
Time HAART initiated
Before pregnancy
On pregnancy
44
33
28
95
<0.0001
22
22
50
106
0.001
CD4 level (cell/mm3)
<200
201-350
>351
39
30
20
45
92
161
<0.0001
38
19
12
46
103
169
<0.0001
WHO clinical stage
I
II
III
IV
14
17
33
25
92
122
64
46
<0.0001
7
10
29
23
99
129
68
48
<0.0001
Gestational age at birth
>=37 weeks
<37weeks
34
55
313
14
<0.0001
Mode of labor
Induced
Spontaneous
5
84
31
296
0.25
6
63
30
317
0.98
Mode of delivery
Spontaneous vaginal
Assisted/instrumental
Operative
77
8
4
269
37
21
0.62
56
8
5
290
37
20
0.86
NB: variables with P value less than 0.2 were entered into the multivariate analysis
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Table 5: Bivariate and multivariate analysis of associated factors of low birth weight
among infant born to HIV infected women in Public Hospitals of North Gondar zone,
Northwest Ethiopia from September1, 2009 to April 10, 2012
Factors LBW OR(95%C.I)
Yes no COR AOR
Maternal CD4 level(cells/mm3)
<200
201-350
>351
39
30
20
45
92
161
6.97[3.70,13.13]
2.62[1.41,4.88]
1
4.24[1.85,9.69]*
1.13[0.53,2.37]
1
Maternal WHO clinical stage
Stage I
Stage II
Stage III
Stage IV
14
17
33
25
92
122
64
46
1
0.91[0.42,1.95]
3.38[1.68,6.83]*
3.57[1.69,7.51]*
Maternal BMI
<18.499
>18.5
43
40
34
230
7.27[4.14,12.74]
1
5.50[2.82,10.74]*
1
HAART exposure
No
yes
12
77
204
123
1
10.64[5.56,20.34]
1
8.26[2.53,14.34]*
Obstetric complications
None
APH
Anemia
Eclamsia
PROM
56
2
14
4
12
255
18
8
10
27
1
0.50[0.11,2.24]
7.96[3.19,19.90] *
1.82[0.55,6.01]
2.02[0.96,4.23]
Gestational age
>=37 weeks
<37 weeks
34
55
313
14
1
36.16[18.22,71,75]
1
28.14[12.69,62.34]*
*significant
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Table 6: Bivariate and multivariate analysis of associated factors of preterm delivery
among infant born to HIV infected women in North Gondar zone, Northwest Ethiopia
from September1, 2009 to April 10, 2012
factors PD OR((95% C.I)
Yes no COR AOR
Maternal CD4 level/cells/mm3
<200
201-350
>351
38
19
12
46
103
169
11.63[5.62,24.05]
2.59 [1.21, 5.57]
1
5.37[1.86, 15.49]*
0.83[0.28,2.41]*
1
Maternal WHO clinical stage
Stage I
Stage II
Stage III
Stage IV
7
10
29
23
99
129
68
48
1
1.09[0.40, 2.99]
6.03[2.49, 14.55]*
6.77[2.71, 16.89]*
Maternal BMI
<18.499
>18.5
34
27
43
243
7.11[3.90, 12.97]
1
4.52 [2.39, 9.27]*
1
Time HAART initiated
Before pregnancy
On pregnancy
22
22
50
106
2.12[1.07, 4.18]
1
1.82[1.02,3.81]*
1
Obstetric complications
None
APH
Anemia
Eclamsia
PROM
40
2
8
5
13
271
18
14
9
26
1
0.75[0.16,3.36]
3.87[1.52,9.81]*
3.76[1.20,11.79]*
3.38[1.61,7.12]*
PMTCT intervention
No
Yes
24
45
62
285
2.45[1.39,4.32] *
1
1.53[1.24, 3.05]*
1
HAART exposure
No
Yes
25
44
191
156
1
2.15[1.26,3.67]*
*significant
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6. Discussion
While HIV/AIDS is not a major direct cause of neonatal death, maternal HIV status
affects newborn survival by causing an increased risk of preterm, low birth weight and
death in the neonatal period and infancy, even among those babies who do not become
HIV-positive.(22) Preterm birth and low birth weight are the most common direct cause
of newborn mortality. LBW contributes to 60% to 80% of all neonatal deaths (21).
The rate of low birth weight (21.4%) and preterm delivery (16.6%) in this study is higher
than the global report (20) which is (15.5%)  and the total prevalence rate in Ethiopia
(15%) (18). The prematurity rate among HIV-infected pregnant women was twice than
that in the general population according to study in France showed(63) and this study
showed higher LBW and preterm delivery rate among HIV positive pregnant mothers
than the general population. The current prevalence of low birth weight is almost
comparable to study conducted in South Africa which is 22%(15),Ghana(22.5%) (64)
and china(19.6%) (28) but higher than study from Tanzania(11.1%)
(19),Thailand(12.6%) (65) and India (12.6%) (30) and higher rate of preterm delivery
than in south Africa (13.3%) and china(9.8%).
The prevalence of pre-term delivery among HIV infected women in this study is higher
than study from Thailand (37) which was 10.2% and lower than study from Ghana (64)
which is (24.4%). The difference may be due either the treatment for the HIV, the study
setting and time gap of study.  prospective study conducted in Tanzania(19) found
23.5% incidence of preterm birth among HIV positive pregnant women which is higher
than the present study and this difference could be the difference in the design of study.
Multivariate analysis have shown that lower baseline maternal CD4 count level, low
maternal BMI,gestational age at birth below 37weeks and maternal exposure to HAART
had statistically significant association with low birth weight.
Advanced maternal HIV disease is a recognized risk factor for preterm delivery as to the
report of many studies (12, 55, 56) and studies from Kenya showed that HIV-infected
women were 3 times more likely to deliver a low birth- weight baby, especially in the
presence of HIV-related symptoms (25, 29) and the Univariate analysis in this study
showed that advanced maternal WHO clinical stage especially In advanced WHO
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clinical stage III (p=<0.0001) and stage IV(p=<0.0001) were associated with low birth
weight and preterm birth, even though this variable didn’t persist in the multivariate
analysis .This can be explained that mother who are in advanced clinical stage could
had severe cases of opportunistic infections which may affect the mother nutritional
status and the in utero- fetal growth.
Early HAART initiation for all HIV-positive pregnant women (2, 8) and widespread use of
HAART among HIV infected pregnant women has led to dramatic decreases in HIV
transmission to the infant (9, 10) and decreases maternal morbidity(11-13).
However, this study has shown the significant association of maternal HAART exposure
with LBW where those mothers who were on HAART had 8.2 fold increased risk of
having LBW. This is consistent with previous studies demonstrating an association with
preterm birth and in utero HAART exposure.(15) Similar studies suggested that the one
who received HAART during pregnancy had 2.27 times higher risk in having LBW (40)
and study conducted in Poland (39) which revealed that Pre-term deliveries were highly
prevalent among women on HAART during pregnancy. It is also in line with the
prospective study conducted in Côte d’Ivoire(53) where LBW was two-fold higher in the
cohort that took three-drug HAART compared with the cohort that received short-course
ARV prophylaxis. the one who received highly active antiretroviral therapy (HAART) had
2.27 times higher risk in having LBW as to the study in Thailand shown(37). Similarly a
larger study in Botswana found that HAART-exposed infants were smaller for
gestational age than unexposed infants (54). In contrary to this meta-analysis of 14
European and American clinical studies found no increase in risk of either PD or LBW
with either any ARV drug receipt compared with no combination of ARV regimens (12)
and  the risk of LBW were not increased in any drug regimen groups(49).
The current study also report that lower maternal CD4 level is significantly associated
with LBW; especially those with CD4 level below 200cells/mm3 had 4.24 higher risk of
having lower birth weight than those mother with CD4 above 350cells/mm3. This may
be explained as; the severely immuno-compromised mothers also may have many
opportunistic infections and complications. Similar study have shown that women with a
CD4 count <200 cells/mL were nearly twice as likely to have an adverse pregnancy
outcome than those with a cell count of 500 cells/mL or more (16). Recent study in
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china also indicated that Lower CD4 cell count; <100 cell/μl and CD4 cell count 100–
199 cells/μl compared to CD4 ≥350 cells/μl and higher HIV RNA viral load [≥100 000
copies/ml at enrollment were the risk factors for LBW(28). However, one recent study
depicted as there is no difference in LBW and PD among cohort of mothers with <200
CD4 cells and >500 CD4 cells respectively (60).
Poor maternal nutrition may be associated with adverse birth outcome in HIV positive
women and one recent study(66) have revealed as maternal BMI below 21.8 had 1.82
higher risk of preterm delivery and 2.09 higher risk of LBW, and the current study
multivariate analysis have shown 5.50 higher risk of LBW and 4.52 higher risk of
preterm delivery. In relation to this the Univariate analysis showed that obstetric
maternal complication especially maternal anemia during pregnancy had resulted in
3.87(p=0.004) and 7.96(p=<0.0001) higher risk of developing preterm delivery and LBW
respectively. However the factor didn’t persist in the multivariate analysis.
Preterm delivery was associated with low maternal CD4 level, having no PMTCT or
untreated HIV infection among pregnant women, low BMI, mother who were already on
HAART before pregnancy.
Those mothers who had no PMTCT/untreated pregnancy infection had 1.53 fold higher
risk of preterm delivery as compared to the treated group. study conducted in Nigeria
also have shown that  pre-term birth were significantly higher among women with
untreated-HIV infection in pregnancy compared with women who received HAART or
prophylaxis from early pregnancy (52). This suggests the need for more strengthening
of PMTCT intervention programme to decrease pregnancy complication.
Moreover, mother with CD4 level lower than 200 cells/mm3 had 5.37 higher risk of more
preterm birth as compared to those with CD4 levels above 350cells/mm3 and this can
be explained as; the risk severe immuno-suppression will lead the mother to have many
infections and low weight gain. The finding is also consistent with many studies in
Africa(15) and china.(28) However, one recent multi-centric study depicted as there is
no difference in PD among cohort of mothers with <200 CD4 cells and  >500 CD4 cells
respectively(60).
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This study also revealed that women who were already on HAART preconception had
1.82 fold increased risk of having preterm delivery compared to those who started later
on pregnancy.
This finding is consistent with many studies in Europe and Africa. One study have
shown that women who were using ARVs pre-conception had higher rates of PTD (
(26.3% vs. 17.7%) respectively (38, 41). In line with this study conducted by European
collaborative study observed a  2.1-fold increased risk when HAART was started  before
pre-conception (42, 43)and the risk of delivery before 34 weeks’ gestation was 4.4-fold
for those entering pregnancy on combination ARV regimens(42). This finding is also
supported by study conducted in Poland (39) which revealed that Pre-term deliveries
were highly prevalent among women on HAART during pregnancy, especially when
therapy was started before or in the first trimester of pregnancy.
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Limitation of the study
Due to the design of the study and as the study was conducted within routine clinical
settings, this study were unfortunately not able to assess other known risk factors for
LBW and PD which might also be associated with low birth weight and preterm birth like
maternal smoking and alcohol intake history during pregnancy. In addition since the
data are secondary there may be bias.
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7. CONCLUSION AND RECOMMENDATION
Conclusion
The rate of low birth weight and preterm delivery among HIV positive pregnant mother
who gave birth in public hospitals in North Gondar zone is very high. The finding of this
study for the associated factors of low birth weight suggest that low maternal baseline
CD4 count level, low  maternal BMI,preterm delivery, maternal HAART exposure were
risk factors for low birth weight.
On the other hand low baseline maternal CD4 count level, having no PMTCT
intervention/untreated HIV infection, low maternal BMI, and mother who were on
HAART before pregnancy were associated with preterm delivery. This suggests the
need for early intervention to increase the maternal CD4 level and reduce the infections
before conception in those mothers with intention to have child. The findings are
consistent with many African and European based study.
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RECOMENDATION
To health institutions /Hospitals, health centers;
 The earlier identification and treatment of mothers before their conception to delay
conception until CD4 cell count increased and HIV viral load decrease, especially in
those in advanced clinical stage.
 Encouraging and educating severely immuno-compromised HIV-infected women
who plan to become pregnant to wait until immune restoration may help to reduce
the risk of LBW and PD.
 Family planning programme should be strengthened more, giving special attention to
HIV infected mothers especially who are on HAART and in advanced clinical stage
to delay pregnancy
 Strengthening education and nutritional supplementation for HIV infected mothers.
 Strengthening PMTCT services not to miss treatment for all HIV infected women
having intention to have children.
For HIV positive mothers;
 It is better if the mothers report early to their doctors when they have intention to
give birth so as to get appropriate advice and intervention before conception.
For researchers:
 It would be very important if further prospective kind of study is done in future to
further deal on the problem by including the other important variables.
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9. ANNEXES
9. 1 Data extraction format
no VARIABLES Delivery Chart no :----------- ANC/PMTCT card no ----- ART clinic
chart no …………………..
Site of data
collection
Gondar hospital
Debark hospital
Metemma Hospital
A. CURRENT BIRTH OUTCOME HISTORY
1 Infant date of birth
2 Infant place of birth
3 Sex of newborn Male
Female
4 Birth weight
5 Gestational age at delivery <34 weeks
34-37weeks
>37weeks
6 Apgar score at 5 minute
Admission to Neonatal care unit for newborn
complications
1. Yes
2. no
8 maternal weight 1. Baseline:__________
2. 2nd visit:_____________
3. 3rd Visit:______________
9 maternal height
10 BMI
12 Condition of newborn/fetal outcome 1. alive
2. still birth
3. early death
4. birth
defect:_________________
14 Mode of labor 1. induced b/c of
complication
2. normal  labor
15 Mode of delivery 1. Normal vaginal
2. Instrumental
3. C/s before labor
4. C/s after labor/PROM
5. others
B. MOTHER SOCIODEMOGRAPHIC HISTORY
44
18 Age of mother at delivery
19 residence 1. Urban
2. rural
20 Educational level 1. Uneducated
2. Primary
3. Secondary
4. college
21 occupation 1. Gov’t employee
2. Merchant
3. Daily laborers
4. Housewife
5. other
22 Marital status 1. Single
2. Married
3. Divorced
4. Widowed
5. separated
23 religion 1. Orthodox
2. Muslim
3. Protestant
4. others
24 parity 1. Primigravida
2. multigravida
16 gravidity 1. Primigravida
2. multigravida
C. OBSTETRIC HISTORY
20 Obstetric complications? 1. APH
2. PROM
3. Anemia
4. others
21 ANC follow-up? 1. Yes
2. No
22 Duration of ANC? 1. Once
2. Twice
3. Three times
4. >three
D. ARVS TREATMENT AND FOLLOW UP HISTORY
26 When mothers HIV infection known? 1. Before pregnancy
2. On pregnancy
3. On delivery (unbooked)
28 Duration on Cotrimoxazole during
pregnancy?
1. Not at all/no cotrimoxazole
2. <10weeks
3. 10-16weeks
4. 16-32weeks
5. >32weeks
6. The whole duration of pregnancy
45
29 What type of ARVs treatment the mother
was given during pregnancy?
1. HAART
2. Short course regimen prophylaxis
3. other
27 When is this ARVs prophylaxis started? 1. Before current pregnancy
2. After pregnancy
28 If ARV prophylaxis started on
pregnancy; when?
1. >=37weeks
2. 28-36weeks
3. 15-27weeks
4. <=14weeks
29 What type of short course
regimen/prophylaxis given?
1. AZT monotherapy
2. sdNVP
3. sdNVP+ AZT
4. sdNVP+ AZT+3TC
5. only Cotrmoxazole
30 When is the HAART started? 1. Before current pregnancy
2. After pregnancy
31  If HAART started before current
pregnancy:
when is her pregnancy reported to
ANC clinic or Doctor?
1. >=37weeks
2. >28-36weeks
3. 15-27weeks
4. <=14weeks
33 If HAART started on pregnancy when (at
what gestational age) it started?
1. >=37weeks
2. >28-36weeks
3. 15-27weeks
4. <=14weeks
34 Median duration on HAART before
delivery?
1. <5 weeks
2. 5-6weeks
3. 7-8 weeks
4. >8weeks
35 HAART regimen type?
38 Baseline CD4 level of pregnant mother? 1. <200 ml/d
2. 200-350 ml/d
3. 350-500 ml/d
4. >500 ml/d
41 Baseline WHO stage on pregnancy? 1. Stage I Stage II
2. Stage III Stage IV
42 Treatment complications on pregnancy: 1. No complications
2. Anemia
3. Toxicities
4. treatment failure
43 COMORBIDITIES 1. DM 2. HTN
3.TB on pregnancy
2. STI 5.Treatment for
malaria
44 Treated for TB on Pregnancy? 1. Yes 2.No
45 Treated for STI on pregnancy? 1. Yes No
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9.2. Fig 1: Conceptual framework showing predicting factors of birth Outcome among
HIV infected Women
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